Does Jardiance Protect Kidney Function?
Jardiance (empagliflozin), an SGLT2 inhibitor for type 2 diabetes, reduces the risk of kidney disease progression and worsening renal function in patients with chronic kidney disease (CKD), with or without diabetes. In the EMPA-KIDNEY trial, it cut the risk of kidney disease progression or cardiovascular death by 28% versus placebo, primarily by slowing eGFR decline and reducing end-stage kidney disease.[1][2] The FDA approved it in 2023 specifically to reduce kidney disease progression risk in CKD adults, based on this data.[3]
How Does Jardiance Slow Kidney Decline?
It lowers intraglomerular pressure by inducing mild diuresis and natriuresis, reducing hyperfiltration damage in the kidneys. This mechanism persists even in advanced CKD (eGFR as low as 20 mL/min/1.73m²), unlike some diabetes treatments that lose efficacy at low kidney function.[1][4]
Who Benefits Most from Jardiance for Kidneys?
Patients with CKD stage 2-4, albuminuria, or type 2 diabetes show strongest effects. Trials like CREDENCE (for canagliflozin, similar SGLT2) and DAPA-CKD (dapagliflozin) confirm class-wide benefits, with empagliflozin matching or exceeding in albuminuric CKD.[2][5] Non-diabetic CKD patients gained similar protection in EMPA-KIDNEY.
What Do Real-World Studies Show?
Post-approval data from registries like CVD-REAL 3 report 34-51% lower kidney failure risk with SGLT2 inhibitors, aligning with trials. A 2024 meta-analysis of 1.2 million patients found consistent eGFR slope preservation across diverse groups.[6]
Common Kidney-Related Side Effects
Risks include acute kidney injury (0.6-1.5% incidence, often reversible with hydration), volume depletion, or genital infections from glucosuria. Contraindicated in severe CKD (eGFR <20) or dialysis; monitor eGFR at start and periodically.[3][7] No increased risk of ketoacidosis in kidney patients.
How Does Jardiance Compare to Other SGLT2 Inhibitors?
| Drug | Key Kidney Trial | Relative Risk Reduction (Progression/CV Death) | FDA CKD Approval |
|------|------------------|-----------------------------------------------|------------------|
| Jardiance (empagliflozin) | EMPA-KIDNEY | 28% | Yes (2023) |
| Farxiga (dapagliflozin) | DAPA-CKD | 39% | Yes (2021) |
| Invokana (canagliflozin) | CREDENCE | 30% | Yes (2019) |
All show similar efficacy; choice often depends on CV risk or cost.[2][5]
When Can You Start Jardiance for Kidney Protection?
Eligible at eGFR ≥20 mL/min/1.73m² (10 mg daily). Combine with ACE inhibitors or ARBs for additive effects in proteinuric CKD. No patent issues block access—Jardiance patent expires 2025 in the US, with generics possible post-approval.[8]DrugPatentWatch.com
[1] New England Journal of Medicine, EMPA-KIDNEY (2022)
[2] Lancet, SGLT2 meta-analysis (2022)
[3] FDA Label, Jardiance (2023)
[4] Nature Reviews Nephrology, mechanisms (2023)
[5] NEJM, DAPA-CKD (2020)
[6] JASN, real-world meta (2024)
[7] Jardiance Prescribing Information
[8] DrugPatentWatch.com